keyword
MENU ▼
Read by QxMD icon Read
search

SLE and dsDNA

keyword
https://www.readbyqxmd.com/read/29325582/urinary-angiostatin-cxcl4-and-vcam-1-as-biomarkers-of-lupus-nephritis
#1
Chi Chiu Mok, Samar Soliman, Ling Yin Ho, Fatma A Mohamed, Faten Ismail Mohamed, Chandra Mohan
BACKGROUND: The aim was to study urinary angiostatin, CXC chemokine ligand 4 (CXCL4) and vascular cell adhesion molecule-1 (VCAM-1) as biomarkers of renal disease in systemic lupus erythematosus (SLE). METHOD: Patients who fulfilled ≥ 4 American College of Rheumatology (ACR) criteria for SLE with active renal, active non-renal or inactive disease, and a group of healthy controls were studied. Urine samples were assayed for angiostatin, CXCL4 and VCAM-1 by ELISA, and normalized by creatinine...
January 11, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29320974/head-to-head-comparison-of-adverse-effects-and-efficacy-between-high-dose-deflazacort-and-high-dose-prednisolone-in-systemic-lupus-erythematosus-a-prospective-cohort-study
#2
A Ganapati, R Ravindran, T David, B Yadav, V Jeyaseelan, L Jeyaseelan, D Danda
Background Deflazacort (DFZ), an oxazoline derivative of prednisolone (PDN), has a dose equivalence of 1.2:1 (mg) to PDN. No study to date has compared adverse effects and efficacy of high doses of DFZ as against high-dose PDN in systemic lupus erythematosus (SLE). Objectives To compare adverse effects of high dose DFZ and PDN in SLE patients, especially in terms of cushingoid features and gain in body weight, 3 and 6 months after initiation of these agents. Methods In both the steroid arms, the following outcome parameters were assessed at 3 and 6 months: (a) cushingoid features by Cushing's Severity Index (CSI) (b) hirsutism by modified Ferriman Gallwey score (c) weight gain by difference (Δ, delta) of weight (in kilograms)...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29308726/efficacy-and-safety-of-anti-cd20-antibody-rituximab-for-patients-with-refractory-systemic-lupus-erythematosus
#3
S Iwata, K Saito, S Hirata, N Ohkubo, S Nakayamada, K Nakano, K Hanami, S Kubo, I Miyagawa, M Yoshikawa, Y Miyazaki, H Yoshinari, Y Tanaka
Objective We examined the efficacy and safety of rituximab in patients with refractory systemic lupus erythematosus (SLE). Methods The study enrolled 63 SLE patients who were treated with rituximab between 2002 and 2015. The participants underwent a battery of tests before treatment and at one year. Treatment ranged from two to four times at 500 or 1000 mg. Results Baseline characteristics were males:females = 6:57, age 33.9 years, and disease duration 87.2 months. The primary endpoint: The rate of major clinical response (MCR) was 60% while the partial clinical response (PCR) was 25%...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29295895/impaired-contraction-of-blood-clots-as-a-novel-prothrombotic-mechanism-in-systemic-lupus-erythematosus
#4
Giang Le Minh, Alina D Peshkova, Izabella A Andrianova, Timur B Sibgatullin, Adelia N Maksudova, John W Weisel, Rustem Litvinov
The aim of this work was to examine a possible role of clot contraction/retraction in thrombotic complications of systemic lupus erythematosus (SLE). Using a novel automated method, we investigated kinetics of clot contraction in the blood of 51 SLE patients and 60 healthy donors. The functionality of platelets in the SLE patients was assessed using flow cytometry by expression of P-selectin and fibrinogen-binding capacity. The rate and degree of clot contraction were significantly reduced in SLE patients compared to healthy subjects, especially in the patients with higher blood levels of anti-dsDNA antibodies...
January 2, 2018: Clinical Science (1979-)
https://www.readbyqxmd.com/read/29287313/multi-center-delphi-exercise-reveals-important-key-items-for-classifying-systemic-lupus-erythematosus
#5
Gabriela Schmajuk, Bimba F Hoyer, Martin Aringer, Sindhu R Johnson, David I Daikh, Thomas Dörner
BACKGROUND: The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) embarked on a project to re-evaluate classification criteria for systemic lupus erythematosus (SLE). The first phase of the classification project involved generation of a broad set of items potentially useful for classification of SLE and their selection for use in a subsequent forced-choice decision analysis. METHODS: A large international group of expert lupus clinicians was invited to participate in a 2-step process to generate, rate and select items based on their importance in diagnosing early and established SLE, respectively, via a web-based survey...
December 29, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29259835/efficacy-of-rituximab-in-a-systemic-lupus-erythematosus-patient-presenting-with-diffuse-alveolar-hemorrhage
#6
Gabriela Montes-Rivera, Grissel Ríos, Luis M Vilá
Diffuse alveolar hemorrhage (DAH) is a life-threatening complication of systemic lupus erythematosus (SLE). Although infrequent, its mortality is very high. While there are no established therapeutic guidelines, DAH has been traditionally managed with high-dose intravenous (IV) corticosteroids, cyclophosphamide, and plasma exchange. The efficacy of alternative therapies such as rituximab has been described only in a few cases. Herein, we report a 25-year-old Hispanic man who presented with acute-onset SLE manifested by polyarthralgia, nephritis, seizures, pancytopenia, severe hypocomplementemia, and elevated anti-dsDNA antibodies...
2017: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/29259790/complement-levels-and-risk-of-organ-involvement-in-patients-with-systemic-lupus-erythematosus
#7
Ignacio Javier Gandino, Marina Scolnik, Emmanuel Bertiller, Valeria Scaglioni, Luis Jose Catoggio, Enrique Roberto Soriano
Objective: Complement plays a major role in SLE. Complement participation has been linked to disease activity and damage. Our objective was to estimate the association of complement behaviour with clinical manifestations, visceral injury and mortality in patients with SLE. Methods: Complement determinations (C3 and C4 levels) were analysed in patients with SLE (fulfilling American College of Rheumatology (ACR) or Systemic Lupus International Collaborating Clinics (SLICC)criteria) seen at a university hospital between 2000 and 2013...
2017: Lupus Science & Medicine
https://www.readbyqxmd.com/read/29233037/serum-wisteria-floribunda-agglutinin-positive-mac-2-binding-protein-can-reflect-systemic-lupus-erythematosus-activity
#8
S S Ahn, Y Park, D D Lee, A L M Bothwell, S M Jung, J J Song, Y-B Park, S-W Lee
Serum Mac-2-binding protein (M2BP) is elevated in various chronic inflammatory diseases, and evidence suggests that glycosylation of M2BP induces discrete biological effects. However, the role of serum M2BP in systemic lupus erythematosus (SLE) is still unclear. Recently, a Wisteria floribunda agglutinin-positive-M2BP (WFA+-M2BP) immunoassay has shown promise in detecting highly glycosylated M2BP. In this study, by using WFA+-M2BP immunoassay, we measured serum M2BP in 203 SLE patients and evaluated its clinical significance...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/29224674/drivers-of-the-immunopathogenesis-in-systemic-lupus-erythematosus
#9
REVIEW
Thomas Rose, Thomas Dörner
This review summarises a number of current insights into the pathogenesis of SLE. On the basis of the interaction of environmental factors within a predisposed host, a chronic autoimmune process gains function with a positive feed-forward loop between innate and adaptive immunity. A current focus of SLE pathogenesis is on the enhanced production of certain cytokines, such as type I interferons and BLyS/BAFF, suggesting continuous plasmacytoid dendritic and myeloid cell activity together with disturbances of B lineage cells (increased autoantibodies, including anti-dsDNA and plasmablasts, which correlate with SLE activity and memory B-cell abnormalities)...
June 2017: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/29214036/strong-viral-associations-with-sle-among-filipinos
#10
Evan S Vista, Michael H Weisman, Mariko L Ishimori, Hua Chen, Rebecka L Bourn, Ben F Bruner, Laniyati Hamijoyo, Robelle D Tanangunan, Noga J Gal, Julie M Robertson, John B Harley, Joel M Guthridge, Sandra V Navarra, Judith A James
Objectives: Epstein-Barr virus (EBV) is considered an important environmental factor in SLE aetiology, but the relationship between SLE and EBV in the Filipino population is unknown. We tested associations between SLE, lupus-associated autoantibodies and seropositivity for EBV and other herpes viruses in the Filipino population. Methods: Sera from Filipino patients with SLE (n=233), unaffected first-degree relatives (FDRs, n=543) and unrelated controls (n=221) were tested for antibodies against EBV, cytomegalovirus (CMV) and herpes simplex viruses (HSV-1 and HSV-2) by standardised ELISAs...
2017: Lupus Science & Medicine
https://www.readbyqxmd.com/read/29208022/role-of-endoplasmic-reticulum-stress-in-the-protective-effects-of-ppar%C3%AE-%C3%AE-activation-on-endothelial-dysfunction-induced-by-plasma-from-patients%C3%A2-with-lupus
#11
Marta Toral, Rosario Jiménez, Miguel Romero, Iñaki Robles-Vera, Manuel Sánchez, Mercedes Salaices, José Mario Sabio, Juan Duarte
BACKGROUND: We tested whether GW0742, a peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) agonist, improves endothelial dysfunction induced by plasma from patients with systemic lupus erythematosus (SLE) involving the inhibition of endoplasmic reticulum (ER) stress. METHODS: A total of 12 non-pregnant women with lupus and 5 non-pregnant healthy women (controls) participated in the study. Cytokines and double-stranded DNA autoantibodies (anti-dsDNA) were tested in plasma samples...
December 6, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29208014/plasma-c4d-as-marker-for-lupus-nephritis-in-systemic-lupus-erythematosus
#12
Myriam Martin, Karolina I Smoląg, Albin Björk, Birgitta Gullstrand, Marcin Okrój, Jonatan Leffler, Andreas Jönsen, Anders A Bengtsson, Anna M Blom
BACKGROUND: In the present study, we sought to evaluate the complement activation product C4d as a marker for lupus nephritis in systemic lupus erythematosus (SLE). METHODS: C4d levels were determined by enzyme-linked immunosorbent assay in plasma samples of patients with established SLE using a novel approach based on detection of a short linear cleavage neoepitope. Cross-sectional associations were studied in 98 patients with SLE with samples taken at lower or higher respective disease activity...
December 6, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29186654/treatment-with-allogenic-mesenchymal-stromal-cells-in-a-murine-model-of-systemic-lupus-erythematosus
#13
Chiara Tani, Sabrina Vagnani, Linda Carli, Francesca Querci, Anja A Kühl, Simone Spieckermann, Constanze Pamela Cieluch, Simone Pacini, Rita Fazzi, Marta Mosca
Objective: Pre-clinical and uncontrolled studies in patients with systemic lupus erythematosus (SLE) showed that mesenchymal stromal cells (MSCs) have a potential therapeutic role in refractory cases. The optimal therapeutic strategy in these patients remain to be elucidated. Our aim was to test the hypothesis that repeated administrations of 1×106/kg body weight of allogenic MSCs, that is a significantly lower dosage with respect to the fixed 1×106 MSC used in animal models, can be effective in improving the clinical course of a murine SLE model...
November 30, 2017: International Journal of Stem Cells
https://www.readbyqxmd.com/read/29185130/increased-lipid-and-protein-oxidation-and-lowered-anti-oxidant-defenses-in-systemic-lupus-erythematosus-are-associated-with-severity-of-illness-autoimmunity-increased-adhesion-molecules-and-th1-and-th17-immune-shift
#14
Bruna Miglioranza Scavuzzi, Andréa Name Colado Simão, Tatiana Mayumi Veiga Iriyoda, Marcell Alysson Batisti Lozovoy, Nicole Perugini Stadtlober, Lorena Flor da Rosa Franchi Santos, Tamires Flauzino, Fabiano Aparecido de Medeiros, Marcelo Cândido de Sá, Luana Consentin, Edna Maria Vissoci Reiche, Michael Maes, Isaias Dichi
This study investigated nitro-oxidative stress in patients with systemic lupus erythematosus (SLE) in association with disease activity, immune-inflammatory biomarkers, and adhesion molecules. Two-hundred-four patients with SLE and 256 healthy volunteers were enrolled in this case-control study, which measured nitro-oxidative stress biomarkers, including lipid peroxides (LOOH), advanced oxidation protein products (AOPPs), nitric oxide metabolites (NOx), sulfhydryl (-SH) groups, products of deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) oxidative degradation, and total radical-trapping anti-oxidant parameter (TRAP)...
November 29, 2017: Immunologic Research
https://www.readbyqxmd.com/read/29180749/clonal-evolution-and-antigen-recognition-of-anti-nuclear-antibodies-in-acute-systemic-lupus-erythematosus
#15
Shuhei Sakakibara, Takao Arimori, Kazuo Yamashita, Hideyuki Jinzai, Daisuke Motooka, Shota Nakamura, Songling Li, Kazuya Takeda, Jun Katayama, Marwa Ali El Hussien, Masashi Narazaki, Toshio Tanaka, Daron M Standley, Junichi Takagi, Hitoshi Kikutani
The evolutional process of disease-associated autoantibodies in systemic lupus erythematosus (SLE) remains to be established. Here we show intraclonal diversification and affinity maturation of anti-nuclear antibody (ANA)-producing B cells in SLE. We identified a panel of monoclonal ANAs recognizing nuclear antigens, such as double-stranded DNA (dsDNA) and ribonucleoproteins (RNPs) from acute SLE subjects. These ANAs had relatively few, but nonetheless critical mutations. High-throughput immunoglobulin sequencing of blood lymphocytes disclosed the existence of sizable ANA lineages shearing critical mutations intraclonally...
November 27, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29178890/cytokine-and-autoantibody-clusters-interaction-in-systemic-lupus-erythematosus
#16
Yovana Pacheco, Julián Barahona-Correa, Diana M Monsalve, Yeny Acosta-Ampudia, Manuel Rojas, Yhojan Rodríguez, Juliana Saavedra, Mónica Rodríguez-Jiménez, Rubén D Mantilla, Carolina Ramírez-Santana, Nicolás Molano-González, Juan-Manuel Anaya
BACKGROUND: Evidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-life settings is a major challenge. Cluster approaches may assist in the identification of these subphenotypes, which represent such a phenomenon, and may contribute to the development of personalized medicine...
November 25, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29164585/expression-and-clinical-significance-of-mir-181a-and-mir-203-in-systemic-lupus-erythematosus-patients
#17
H-S Li, Y Ning, S-B Li, P-Y Shao, S-J Chen, Q Ye, X Heng
OBJECTIVE: MiR-181a plays a critical role in modulating T cell and B cell differentiation, as well as immune response. Its abnormal expression probably participates in the pathogenesis of systemic lupus erythematosus (SLE). MiR-203 is involved in regulating Toll-like receptor and inducing immune tolerance. Abnormal expression or function of miR-203 is related to multiple auto-immune diseases but its role in SLE remains unclear. This study, thus, investigated the serum level of miR-181a and miR-203, to analyze their roles in diagnosing and evaluating SLE...
November 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29151171/clinical-and-serological-associations-of-anti-ribosomal-p0-protein-antibodies-in-systemic-lupus-erythematosus
#18
Yong-Jun Mei, Peng Wang, Chao Jiang, Tao Wang, Lin-Jie Chen, Zhi-Jun Li, Hai-Feng Pan
The purpose of this study is to investigate the clinical and serological associations of anti-ribosomal P0 protein antibodies (anti-Rib-P0) in patients with systemic lupus erythematosus (SLE). The sera of 470 patients with SLE and 124 patients with primary Sjogren's Syndrome (pSS) were collected. Line immunoassay (LIA) was used to detect anti-Rib-P0 and other related antibodies. A complete laboratory evaluation and clinical examination were also performed in each SLE patient. The prevalence of anti-Rib-P0 in SLE patients was significantly higher than that in pSS patients (35...
November 18, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29141377/-the-clinical-significance-of-anti-ubiquitin-c-terminal-hydrolase-l1-autoantibodies-in-the-diagnosis-of-neuropsychiatric-systemic-lupus-erythematosus
#19
Y Meng, H Sun, J J Xu, R Li, Y Wang
Objective: To analyze the clinical significance of anti- ubiquitin C-terminal hydrolase L1(UCHL-1)autoantibodies in neuropsychiatric systemic lupus erythematosus (NPSLE). Methods: Autoantibodies in cerebrospinal fluid specimen of 56 inpatients were detected by using indirect enzyme-linked immunosorbent assay (ELISA) and the fullmedical history and clinical manifestations were analyzed retrospectively. Results: The levels of anti-UCHL-1 autoantibodies in NPSLE group were significant higher than that in other controls (P<0...
November 14, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29113537/systemic-lupus-erythematosus-with-c1q-deficiency-treatment-with-fresh-frozen-plasma
#20
Z Ekinci, K Ozturk
Treatment and outcome of systemic lupus erythematosus (SLE) in C1q deficient patients are rarely reported. The aim of this report is to share our experience about the course of management of three cases diagnosed as SLE with C1q deficiency, in light of present literature. Initial and dominant complaints of three cases from two different families were cutaneous manifestations. One patient was also diagnosed with arthritis and thrombocytopenia. Antinuclear antibody was positive in all cases, whereas anti-dsDNA was negative with normal levels of complement C3, C4 and decreased CH50 activity...
January 1, 2017: Lupus
keyword
keyword
34009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"